Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 15;7(5):100200.
doi: 10.1016/j.shj.2023.100200. eCollection 2023 Sep.

The Genetic Evaluation of Dilated Cardiomyopathy

Quan M Bui  1 , Jeffrey Ding  2 , Kimberly N Hong  1 , Eric A Adler  1
Affiliations
Review

The Genetic Evaluation of Dilated Cardiomyopathy

Quan M Bui et al. Struct Heart. .

Abstract

Dilated cardiomyopathy (DCM) is a common cause of heart failure and is the primary indication for heart transplantation. A genetic etiology can be found in 20-35% of patients with DCM, especially in those with a family history of cardiomyopathy or sudden cardiac death at an early age. With advancements in genome sequencing, the understanding of genotype-phenotype relationships in DCM has expanded with over 60 genes implicated in the disease. Subsequently, these findings have increased adoption of genetic testing in the management of DCM, which has allowed for improved risk stratification and identification of at risk family members. In this review, we discuss the genetic evaluation of DCM with a focus on practical genetic testing considerations, genotype-phenotype associations, and insights into upcoming personalized therapies.

Keywords: Arrhythmias; Cardiovascular genetics; Dilated cardiomyopathy; Genetic cardiomyopathy; Genetic testing; Heart failure.

PubMed Disclaimer

Conflict of interest statement

Eric Adler has equity interest in Rocket Pharmaceuticals and is the Chief Scientific Officer at Lexeo Therapeutics. Quan Bui is a Consultant for Lexeo Therpaeutics. Jeffrey Ding, and Kimberly Hong report no conflicts of interest.

Figures

Figure 1
Figure 1
Practical framework for genetic evaluation of dilated cardiomyopathy.
See this image and copyright information in PMC

References

    1. Mestroni L., Maisch B., McKenna W., et al. Guidelines for the study of familial dilated cardiomyopathies. Eur Heart J. 1999;20(2):93–102. - PubMed
    1. Hershberger R.E., Hedges D.J., Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10(9):531–547. doi: 10.1038/nrcardio.2013.105. - DOI - PubMed
    1. Jordan E., Peterson L., Ai T., et al. Evidence-based assessment of genes in dilated cardiomyopathy. Circulation. 2021;144(1):7–19. doi: 10.1161/CIRCULATIONAHA.120.053033. - DOI - PMC - PubMed
    1. Pugh T.J., Kelly M.A., Gowrisankar S., et al. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med. 2014;16(8):601–608. doi: 10.1038/gim.2013.204. - DOI - PubMed
    1. Wilde A.A.M., Semsarian C., Márquez M.F., et al. European heart Rhythm association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific heart Rhythm Society (APHRS)/Latin American heart Rhythm Society (LAHRS) expert consensus statement on the state of genetic testing for cardiac diseases. Europace. 2022;24(8):1307–1367. doi: 10.1093/europace/euac030. - DOI - PMC - PubMed